Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2025-01-01T06:45:24.769Z Has data issue: false hasContentIssue false
  • English
  • Français

Amiodarone Producing Insidious Optic Neuropathy

Published online by Cambridge University Press:  04 January 2024

Ryan H. Mason ,
Armin Handzic Open the ORCID record for Armin Handzic [Opens in a new window] ,
Prem A. H. Nichani  and
Edward A. Margolin Open the ORCID record for Edward A. Margolin [Opens in a new window]
Ryan H. Mason
Affiliation:
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON, Canada
Armin Handzic
Affiliation:
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON, Canada
Prem A. H. Nichani
Affiliation:
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON, Canada
Edward A. Margolin*
Affiliation:
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON, Canada Department of Medicine, Division of Neurology, University of Toronto, Toronto, ON, Canada
*
Corresponding author: E. A. Margolin; Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

Amiodarone-related optic neuropathytoxic optic neuropathyoptic disk swellingneuro-ophthamology
Type
Neuroimaging Highlight
Information
Canadian Journal of Neurological Sciences , Volume 51 , Issue 4 , July 2024 , pp. 564 - 565
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Raeder, EA, Podrid, PJ, Lown, B. Side effects and complications of amiodarone therapy. Am Heart J. 1985;109:97–83. DOI: 10.1016/0002-8703(85)90238-8.CrossRefGoogle ScholarPubMed
Feiner, LA, Younge, BR, Kazmier, FJ, Stricker, BH, Fraunfelder, FT. Optic neuropathy and amiodarone therapy. Mayo Clin Proc. 1987;62:702–17. DOI: 10.1016/s0025-6196(12)65224-0.CrossRefGoogle ScholarPubMed
Murphy, MA, Murphy, JF. Amiodarone and optic neuropathy: the heart of the matter. J Neuroophthalmol. 2005;25:232–6. DOI: 10.1097/01.wno.0000177290.09649.38.CrossRefGoogle ScholarPubMed
Latini, R, Tognoni, G, Kates, RE. Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet. 1984;9:136–56. DOI: 10.2165/00003088-198409020-00002.CrossRefGoogle ScholarPubMed
Mansour, AM, Puklin, JE, O’Grady, R. Optic nerve ultrastructure following amiodarone therapy. J Clin Neuroophthalmol. 1988;8:231–7.Google ScholarPubMed
Costa-Jussa, FR, Jacobs, JM. The pathology of amiodarone neurotoxicity, I: experimental studies with reference to changes in other tissues. Brain. 1985;108:735–52. DOI: 10.1093/brain/108.3.735.Google ScholarPubMed
Passman, RS, Bennett, CL, Purpura, JM, et al. Amiodarone-associated optic neuropathy: a critical review. Am J Med. 2012;125:447–53 DOI: 10.1016/j.amjmed.2011.09.020.CrossRefGoogle ScholarPubMed